Injectable Bioactive Composites vs RMGI for Proximal Cavities in Primary Molars

Starting soon · Not applicable

Conditions studied: Dental Caries

In brief

This randomized clinical trial aims to evaluate and compare the clinical performance of injectable bioactive composite (Beautifil Flow Plus X, Shofu) versus Resin Modified Glass Ionomer (RMGI) in restoring proximal cavities (Class II) in primary molars of children aged 3-8 years over a 12-month follow-up period, using revised FDI criteria.

Key facts

Study ID

NCT07561216

Run by

Cairo University

People needed

50

Starts

2026-05-01

Expected to finish

2027-09-01

Last updated by the study team

2026-05-01

Who can join

Age: 3 and older, up to 8. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged 3-8 years of both genders
• Cooperative behavior manageable by operators
• Willing to sign informed consent
• Accepts the follow-up period
• Moderate to low caries risk according to Cariogram application
• Posterior primary molar with proximal carious lesion (ICDAS 3 or 4) with no signs or symptoms of pulpal involvement
• Radiographically extending to outer 1/3 of dentin

You may not qualify if…

• Allergy to any restorative materials
• Patients undergoing orthodontic treatment with fixed appliances
• Patients with debilitating systemic diseases
• Children with special needs
• Teeth with previous restorations
• Periapical radiolucencies or sensitivity to percussion
• Mobile teeth
• External or internal resorption
• Cervical carious lesions

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.